NeuroDerm Ltd., an Israeli clinical stage pharmaceutical company which develops drugs for central nervous system (CNS) diseases, announced the launch of its initial public offering of 4.5 million ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC).
The company’s pharmaceuticals are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. It is headquartered in the Rabin Science Park, Rehovot, Israel and over the summer raised $16 million in funding for its efforts to find a cure for Parkisnon’s Disease.
Neuroderm has applied to list its ordinary shares on the NASDAQ Global Market under the ticker symbol “NDRM.”
There is no word yet as to what price will asked for each share or what percentage of the company the shares sold will represent.
Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners, LLC are acting as co-managers for the proposed offering.
The offering will be made only by means of a prospectus. A preliminary prospectus for the offering may be obtained from either Jefferies LLC or Cowen and Company, LLC.
A registration statement related to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that